Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Adrienne E. Balitza"'
Autor:
Keith W. Rickert, Christine Fernandes, Xianzhi Mao, Kathleen E. Coll, George D. Hartman, Bradley K. Wong, Peter J. Manley, Adrienne E. Balitza, Timothy J. Koester, Mark T. Bilodeau, Debra A. McLoughlin, David C. Heimbrook, Rosemary C. McFall, Sean Yu, William R. Huckle, Jackson B. Gibbs, Jennifer M. Shipman, Kenneth A. Thomas, Raju Subramanian, Joseph J. Lynch, Nancy E. Kohl, Leonard D. Rodman, Cynthia Miller-Stein, Laura Sepp-Lorenzino, Carolyn Buser-Doepner
Publikováno v:
Journal of Medicinal Chemistry. 47:6363-6372
A series of N-(1,3-thiazol-2-yl)pyridin-2-amine KDR kinase inhibitors have been developed that possess optimal properties. Compounds have been discovered that exhibit excellent in vivo potency. The particular challenges of overcoming hERG binding act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7803b8fb364a80f776c25f0422cd590b
https://doi.org/10.1021/jm049697f
https://doi.org/10.1021/jm049697f
Autor:
George D. Hartman, Kenneth A. Thomas, Mark T. Bilodeau, Kathleen E. Coll, Keith W. Rickert, Leonard D. Rodman, Adrienne E. Balitza, Rosemary C. McFall, Peter J. Manley
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 13:1673-1677
2,4-Disubstituted pyrimidines were synthesized as a novel class of KDR kinase inhibitors. Evaluation of the SAR of the screening lead compound 1 (KDR IC(50)=105 nM, Cell IC(50)=8% inhibition at 500 nM) led to the potent 3,5-dimethylaniline derivative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::021d1bb9daf7639be702b1e7ab112c01
https://doi.org/10.1016/s0960-894x(03)00244-0
https://doi.org/10.1016/s0960-894x(03)00244-0
Autor:
Deborah Defeo-Jones, Anthony M. Smith, Ronald G. Robinson, Mark T. Bilodeau, Stanley F. Barnett, George D. Hartman, Raymond E. Jones, Karen R. Leander, Jacob M. Hoffman, Peter J. Manley, Adrienne E. Balitza, Kathleen M. Haskell, Hans E. Huber
Publikováno v:
Bioorganicmedicinal chemistry letters. 18(11)
A series of naphthyridine and naphthyridinone allosteric dual inhibitors of Akt1 and 2 have been developed. These compounds have been optimized to have potent dual activity against the activated kinase as well as the activation of Akt in cells. One m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0a639621144e65e5990ceb0f62ca51f
https://pubmed.ncbi.nlm.nih.gov/18479914
https://pubmed.ncbi.nlm.nih.gov/18479914
Autor:
Kathleen E. Coll, Jennifer M. Shipman, Zhicai Wu, Keith W. Rickert, Laura Sepp-Lorenzino, Edward S. Tasber, Mark E. Fraley, Bin Shi, Mildred L. Kaufman, Mark T. Bilodeau, Kenneth A. Thomas, Adrienne E. Balitza, George D. Hartman
Publikováno v:
Bioorganicmedicinal chemistry letters. 14(4)
3,7-Diarylsubstituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d43b5f6a420e0d7f262355706bd97df
https://pubmed.ncbi.nlm.nih.gov/15012992
https://pubmed.ncbi.nlm.nih.gov/15012992